Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2019 08:05 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019

NORCROSS, Ga., May 10, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to...
May 10, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update

Subscription rights to purchase Galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April 29. Rights expire at 5:00 PM Eastern on May 23, 2019 ...
April 15, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement

NORCROSS, Ga., April 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has set key...
April 02, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

NORCROSS, Ga., April 02, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold...
March 22, 2019 10:19 ET | Source: Galectin Therapeutics Inc.

Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology

NORCROSS, Ga., March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins,...
March 06, 2019 08:03 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders

NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to...
March 06, 2019 08:02 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants

NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration Statement...
March 06, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update

Planning for Phase 3 clinical trial (NASH-RX) nearing completion for GR-MD-02, the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis NORCROSS, Ga.,...
February 25, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at Berenberg NASH Day in New York

NORCROSS, Ga., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
January 15, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure

NORCROSS, Ga., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its largest...